Cardiovascular adverse events of ibrutinib

被引：14
|
作者：
Ahn, Inhye E. [1 ]
机构：
[1] NHLBI, Bldg 10, Bethesda, MD 20892 USA
来源：
BLOOD | 2019年 / 134卷 / 22期
关键词：
D O I：
10.1182/blood.2019002805
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Dickerson et al report on the increased incidence and worsening severity of hypertension and its association with cardiovascular outcomes in 562 patients treated with ibrutinib for B-cell malignancies.(1)
引用
收藏
页码：1881 / 1882
页数：2
相关论文
共 50 条
  • [1] Ibrutinib-associated cardiovascular adverse events
    Reactions Weekly, 2019, 1773 (1) : 6 - 6
  • [2] Cardiovascular Adverse Events Associated with Ibrutinib in Chronic Lymphocytic Leukemia Patients
    George, Binsah
    Thompson, Philip A.
    Ferrajoli, Alessandria
    Burger, Jan A.
    Wierda, William G.
    O'Brien, Susan M.
    Durand, Jean-Bernard
    Keating, Michael J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S208 - S208
  • [3] Ibrutinib Linked to Hypertension and Cardiovascular Events
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 92 - 93
  • [4] Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib
    Kaur, Varinder
    Swami, Arjun
    ANNALS OF HEMATOLOGY, 2017, 96 (07) : 1175 - 1184
  • [5] Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib
    Varinder Kaur
    Arjun Swami
    Annals of Hematology, 2017, 96 : 1175 - 1184
  • [6] Cutaneous adverse-events in patients treated with Ibrutinib
    Pileri, Alessandro
    Guglielmo, Alba
    Agostinelli, Claudio
    Evangelista, Valeria
    Bertuzzi, Clara
    Alessandrini, Aurora
    Bruni, Francesca
    Starace, Michela
    Massi, Alice
    Broccoli, Alessandro
    Patrizi, Annalisa
    Zinzani, Pier Luigi
    Piraccini, Bianca Maria
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [7] Hypertension and incident cardiovascular events following ibrutinib initiation
    Dickerson, Tyler
    Wiczer, Tracy
    Waller, Allyson
    Philippon, Jennifer
    Porter, Kyle
    Haddad, Devin
    Guha, Avirup
    Rogers, Kerry A.
    Bhat, Seema
    Byrd, John C.
    Woyach, Jennifer A.
    Awan, Farrukh
    Addison, Daniel
    BLOOD, 2019, 134 (22) : 1919 - 1928
  • [8] Evaluation of Cardiovascular Adverse Events Associated With Ibrutinib, Venetoclax and Idelalisib Used in Treatment of Chronic Lymphocytic Leukemia.
    Mahida, Hetavi
    Gharia, Bharatsinh
    Ugoeke, Nene
    Maludum, Obiora
    Asif, Arif
    Calderon, Dawn
    CIRCULATION, 2018, 138
  • [9] Esmolol: adverse cardiovascular events
    Reactions Weekly, 2002, 888 (1) : 4 - 4
  • [10] Campylobacteriosis may masquerade as ibrutinib-related adverse events
    Reactions Weekly, 2022, 1899 (1) : 7 - 7
12345